Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Berkowitz

Showing results (431-440 of 497) with videos related to

Pageof 50
Sort By:
JACC. Cardiovascular Interventions|August 20, 2016
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF TrialMatthew W Sherwood, Derek D Cyr, W Schuyler Jones, et al.
European Heart Journal|March 25, 2014
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trialJonathan P Piccini, Jyotsna Garg, Manesh R Patel, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 30, 2021
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trialThomas Vanassche, Peter Verhamme, Sonia S Anand, et al.
American Heart Journal|September 21, 2015
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)Sameer Bansilal, Zachary Bloomgarden, Jonathan L Halperin, et al.
Circulation|April 11, 2001
Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopeniaB E Lewis, D E Wallis, S D Berkowitz, et al.
The New England Journal of Medicine|December 7, 2010
Oral rivaroxaban for symptomatic venous thromboembolism, Rupert Bauersachs, Scott D Berkowitz, et al.
Nuclear Medicine and Biology|May 7, 2016
[(124)I]FIAU: Human dosimetry and infection imaging in patients with suspected prosthetic joint infectionXiaoyan M Zhang, Halle H Zhang, Patrick McLeroth, et al.
American Heart Journal|February 11, 2021
Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AFVanessa Blumer, Manuel Rivera, Ramón Corbalán, et al.
The New England Journal of Medicine|August 12, 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationManesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, et al.
Journal of the American Heart Association|March 10, 2016
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AFSean D Pokorney, Jonathan P Piccini, Susanna R Stevens, et al.
Pageof 50

Showing results (431-440 of 497) with videos related to

Sort By:
Pageof 50
JACC. Cardiovascular Interventions|August 20, 2016
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF TrialMatthew W Sherwood, Derek D Cyr, W Schuyler Jones, et al.
European Heart Journal|March 25, 2014
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trialJonathan P Piccini, Jyotsna Garg, Manesh R Patel, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 30, 2021
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trialThomas Vanassche, Peter Verhamme, Sonia S Anand, et al.
American Heart Journal|September 21, 2015
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)Sameer Bansilal, Zachary Bloomgarden, Jonathan L Halperin, et al.
Circulation|April 11, 2001
Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopeniaB E Lewis, D E Wallis, S D Berkowitz, et al.
The New England Journal of Medicine|December 7, 2010
Oral rivaroxaban for symptomatic venous thromboembolism, Rupert Bauersachs, Scott D Berkowitz, et al.
Nuclear Medicine and Biology|May 7, 2016
[(124)I]FIAU: Human dosimetry and infection imaging in patients with suspected prosthetic joint infectionXiaoyan M Zhang, Halle H Zhang, Patrick McLeroth, et al.
American Heart Journal|February 11, 2021
Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AFVanessa Blumer, Manuel Rivera, Ramón Corbalán, et al.
The New England Journal of Medicine|August 12, 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationManesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, et al.
Journal of the American Heart Association|March 10, 2016
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AFSean D Pokorney, Jonathan P Piccini, Susanna R Stevens, et al.
Pageof 50